Skip to main content
Clinical Trials/NCT02535923
NCT02535923
Completed
Not Applicable

CBT-I for Psychosis: Guidelines, Preliminary Efficacy, and Functional Outcomes

VA Office of Research and Development1 site in 1 country47 target enrollmentMarch 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Insomnia
Sponsor
VA Office of Research and Development
Enrollment
47
Locations
1
Primary Endpoint
Insomnia Severity Index (ISI)
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The goal of this project is to develop guidelines for the clinical tailoring of Cognitive Behavioral Therapy for Insomnia (CBT-I) for Veterans with psychotic disorders and insomnia, and to test the acceptability, feasibility, and preliminary efficacy of CBT-I for improving sleep-related functional outcomes in this population.

Detailed Description

The goal of this project is to develop guidelines for the clinical tailoring of Cognitive Behavioral Therapy for Insomnia (CBT-I) for Veterans with psychotic disorders and insomnia, and to test the acceptability, feasibility, and preliminary efficacy of CBT-I for improving sleep-related functional outcomes in this population. Specific Aim 1: Develop empirically-derived guidelines for the clinical tailoring of CBT-I materials and procedures for Veterans with psychotic disorders through an iterative process with input from Veteran clients, CBT-I experts and providers, as well as those with expertise in psychotic disorders. Specific Aim 2: Establish the acceptability of CBT-I for Veterans with psychotic disorders and insomnia when delivered using guidelines developed in Specific Aim 1 in order to make further refinements to the guidelines in a preliminary trial with 6 Veterans with psychosis and insomnia. Specific Aim 3: Conduct a randomized controlled trial (n=60) to test the feasibility and preliminary efficacy of CBT-I in producing positive changes at post-treatment and 3-month follow-up on the outcomes of insomnia symptoms, sleep quality, and functioning.

Registry
clinicaltrials.gov
Start Date
March 1, 2018
End Date
April 20, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnostic and Statistical Manual of Disorders, 5th edition (DSM 5) diagnosis of schizophrenic disorders (295.0-295.9), affective psychoses (296.0-296.1, 296.4-296.8), or major depression with psychotic features (296.24, 296.34).
  • Self-reported symptoms of insomnia via an Insomnia Severity Index (ISI) score of 15 or greater.
  • Age between 18 and 80 as determined by medical record review.
  • Participation in outpatient mental health services at a designated study site.
  • Sufficient clinical stability to participate as deemed by a treatment provider.
  • Capacity to sign Informed Consent.

Exclusion Criteria

  • Current problematic drug or alcohol use that impacts functioning and study engagement, as deemed by a treatment provider.
  • Currently in CBT-I treatment, determined by medical records.
  • Positive screen for sleep apnea via a portable sleep apnea screening device or a prior diagnosis of sleep apnea in medical records.

Outcomes

Primary Outcomes

Insomnia Severity Index (ISI)

Time Frame: Participants will be assessed following completion of the study intervention, an expected average of 10 weeks.

ISI score; scored on a scale of 0 to 28, with higher scores indicating worse insomnia severity.

Secondary Outcomes

  • Veterans RAND 36-Item Health Survey Mental Component Score(Participants will be assessed a second time following completion of the study intervention, an expected average of 22 weeks.)
  • Insomnia Severity Index (ISI)(Participants will be assessed a second time following completion of the study intervention, an expected average of 22 weeks.)
  • World Health Organization Disability Assessment Schedule (WHO-DAS), Participation in Society Subscale(Participants will be assessed a second time following completion of study intervention, an estimated average of 22 weeks.)

Study Sites (1)

Loading locations...

Similar Trials